Mitochondrial & metabolic reprogramming

One of 6 mechanistic pathways to 🔥 Lose fat · 29 options

This is the pathway Cam means when he says stretch and extrapolate. Instead of eating less, you change how much energy the cell burns and how efficiently it burns it — mitochondrial biogenesis, uncoupling, NAD+ availability, PGC-1α. Almost nothing here has a human fat-loss trial. The mechanisms are well characterized and the rodent data is often striking. That gap is the opportunity and the risk in one.

🩸 Is this pathway actually your problem?

There is no direct 'mitochondrial function' blood test, which is worth saying plainly. What you can check is whether the cofactors that machinery needs are present — carnitine, CoQ10, thiamine, magnesium. Deficiency here explains fatigue-with-normal-labs, and correcting it is cheaper and better evidenced than anything else in this pathway.

Carnitine, Total and FreeCoenzyme Q10Vitamin B1 (Thiamine)Magnesium, RBCHbA1c (Hemoglobin A1c)

🍭 Metabolic Health & Prediabetes covers these in one panel →

What engages this pathway

Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.

🧬 Garcinia Cambogia

Hydroxycitric acid is a genuine competitive inhibitor of ATP-citrate lyase, the enzyme feeding de novo lipogenesis. The reason a real enzyme block produces a null result is the best thing on the page: humans on a mixed Western diet make comparatively little fat from carbohydrate, so blocking the pathway removes a small slice. Carries a documented hepatotoxicity literature, and the proposed mechanism of the harm is the same enzyme block.

🧪 Theoretical / mechanistic

🧬 7-Keto

3-acetyl-7-oxo-DHEA, sold as the non-androgenic DHEA metabolite that raises resting metabolic rate through hepatic thermogenic enzymes. Its own pharmacokinetic study never detected the parent compound in blood — only the sulfate — and the measured RMR effect is small. WADA lists it, which matters if you compete.

🧪 Theoretical / mechanistic

💉 Indolepropionamide

Sold as IPAM and constantly confused with Ipamorelin, which is a different molecule entirely. The literature everyone cites belongs to indole-3-propionic ACID, a gut-bacterial tryptophan metabolite with a strong human association to lower diabetes risk; what is on sale is the AMIDE, whose entire published record as a substance is one paper in isolated mitochondria and rotifers. Whether an oral amide dose raises serum acid has never been measured.

🧪 Theoretical / mechanistic

💉 MOTS-c

A mitochondrially-encoded peptide that activates AMPK and shifts the cell toward fat oxidation and glucose uptake. In mice it prevents diet-induced obesity and reverses age-dependent insulin resistance. Human trials for fat loss do not exist — but the mechanism is exactly what you'd design if you wanted metabolic flexibility back.

🧪 Theoretical / mechanistic

💉 SLU-PP-332

An ERRα agonist — an exercise mimetic. Rodents given it increase fat oxidation and running capacity without training. Rodent-stage, and the honest read is that nobody knows the human dose, kinetics or safety. The mechanistic case is genuinely excellent.

🧪 Theoretical / mechanistic

💉 SLU-PP-915

A more selective ERRα analog from the same program, tuned to reduce off-target activity. Even earlier than SLU-PP-332 — the argument is entirely by analogy.

🧪 Theoretical / mechanistic

💉 Bam15

A mitochondrial uncoupler that dissipates the proton gradient as heat rather than capturing it as ATP. Unlike DNP it has a wide therapeutic window in rodents and does not raise body temperature dangerously. In mice it drops fat mass while sparing muscle and without touching food intake — which is the whole appeal. Rodent-stage.

🧪 Theoretical / mechanistic

💉 SANA

Sold as a nitroalkene salicylate derivative aimed at creatine-associated thermogenesis. The interesting claim is a futile cycle: creatine shuttling between phosphocreatine and creatine burns ATP as heat instead of banking it, which would be a genuinely different lever from appetite or beta-adrenergic drive. Proposed rather than demonstrated in people.

🧪 Theoretical / mechanistic

💉 5-Amino-1MQ

Inhibits NNMT, an enzyme that clears nicotinamide out of the salvage pathway. Block it and the adipocyte's NAD+ pool rises, SIRT1 activity increases, and stored lipid gets mobilized. Mouse data shows fat loss without appetite change; the human trial hasn't run.

🧪 Theoretical / mechanistic

💉 AICAR

A direct AMPK activator — the master fuel-sensing switch. Cells behave as though they've just trained. Endurance and glucose disposal improve in rodents; the human obstacle is that it is poorly bioavailable and expensive at any dose that would matter.

🧪 Theoretical / mechanistic

💉 ATX-304

A newer, more drug-like pan-AMPK activator built to fix AICAR's bioavailability problem. Early human safety work exists; fat-loss efficacy does not.

🧪 Theoretical / mechanistic

💉 SR-9009

A REV-ERB agonist that increases mitochondrial content and shifts the circadian metabolic program. Famous rodent endurance data. Its oral bioavailability is close to nil, so most of what people report is unlikely to be the mechanism.

🧪 Theoretical / mechanistic

💉 Cardarine (oral/inj) Gw-501516

PPARδ agonism — upregulates the fat-oxidation gene program in muscle and shifts substrate use away from glucose. The rodent carcinogenicity signal at high chronic doses is why it carries a flag, and it is a real one worth understanding before deciding.

🧪 Theoretical / mechanistic⚠ Safety flag

💉 Nad+

Raising the NAD+ pool restores sirtuin and PARP activity that declines with age; the downstream prediction is better mitochondrial function and substrate handling. IV NAD+ has poor evidence for fat loss specifically — the mechanism is upstream of it, not aimed at it.

🧪 Theoretical / mechanistic

🧬 NMN

An NAD+ precursor one step from NAD+. Human trials show the pool rises; whether that translates into fat loss is unestablished and probably depends on how depleted you were.

🧪 Theoretical / mechanistic

💉 NR

Nicotinamide riboside, the better-characterized precursor. Raises NAD+ reliably in humans. Metabolic endpoints in trials have been underwhelming, which is worth knowing before you build a stack on it.

🧪 Theoretical / mechanistic

💉 SS-31

Binds cardiolipin in the inner mitochondrial membrane and restores cristae architecture — repair rather than stimulation. In clinical development for mitochondrial myopathy, not for fat loss; the extrapolation is that a repaired mitochondrion oxidizes substrate better.

🧪 Theoretical / mechanistic

💉 Humanin

Another mitochondrially-derived peptide, cytoprotective and insulin-sensitizing in animals. Very early, very interesting, and essentially no human work.

🧪 Theoretical / mechanistic

💉 Meldonium

Inhibits carnitine biosynthesis, which paradoxically shifts the heart and muscle toward glucose oxidation and away from fat. That is the opposite of what a fat-loss stack wants — it's here so you understand why it doesn't belong.

🧪 Theoretical / mechanistic

💉 Methylene Blue

At low doses acts as an alternative electron carrier, bypassing damaged complexes in the electron transport chain. The prediction is better ATP yield and modestly raised metabolic rate. Serotonin-syndrome risk with SSRIs is the real constraint.

🧪 Theoretical / mechanistic⚠ Safety flag

🧬 Urolithin A

Induces mitophagy — clearing damaged mitochondria so the surviving pool works properly. Human trials show improved muscle endurance and mitochondrial gene expression; body-composition change is not the endpoint that moved.

✅ Clinically validated

🧬 Berberine

Activates AMPK through mild complex-I inhibition. Human trials show meaningful glucose and lipid improvement; the weight effect is smaller than the internet claims and is downstream of the metabolic change.

✅ Clinically validated

🧬 Dihydroberberine

Reduced berberine with substantially better absorption, so a lower dose reaches the same plasma exposure. The efficacy argument is entirely pharmacokinetic.

🧪 Theoretical / mechanistic

🧬 NR (Nicotinamide Riboside)

NiaCel — the NR form with the most human pharmacokinetic data. Raises NAD+ reliably. What that buys you metabolically is the open question.

✅ Clinically validated

🧬 PQQ

Stimulates mitochondrial biogenesis via PGC-1α signaling in cell and animal work. More mitochondria should mean more oxidative capacity; the human body-composition trial doesn't exist.

🧪 Theoretical / mechanistic

🧬 CoQ10

Essential electron carrier in the respiratory chain. Deficiency impairs oxidative metabolism, so repletion matters — but supplementing a replete person is unlikely to change substrate handling.

📊 Correlative

🧬 Alpha Lipoic Acid

Mitochondrial cofactor and AMPK modulator. Meta-analyses show a small but consistent weight reduction, plus genuine insulin-sensitivity benefit.

✅ Clinically validated

🧬 Acetyl-L-Carnitine

Shuttles fatty acids into the mitochondrion for β-oxidation. The catch: carnitine is rarely the rate-limiting step in a healthy person, which is why supplementation underperforms the mechanism.

🧪 Theoretical / mechanistic

🧬 Calcium AKG

A TCA-cycle intermediate with rodent lifespan and body-composition data. Mechanistically upstream of everything metabolic; human evidence is thin.

🧪 Theoretical / mechanistic
Nothing here is ranked by evidence tier. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for. The tier is a label. The mechanism is the map.

What actually decides this outcome, in order of size

This page proposes changing how much energy a cell spends rather than how much arrives. The mechanisms are real and almost none has a human trial with a body-composition endpoint. Ranked by how much of the outcome each factor owns:

  1. THERAPEUTIC INDEX, WHICH FOR AN UNCOUPLER IS THE ENTIRE DESIGN PROBLEM. Uncoupling dissipates the proton gradient as heat. The dose that produces a useful increase in expenditure and the dose that produces uncontrolled hyperthermia are close together, and 2,4-dinitrophenol is the historical proof: it is documented as a weight loss agent with significant acute toxicity Grundlingh 2011. That is not a cautionary anecdote. It is the reason Bam15 exists as a molecule at all — a mitochondrial uncoupler characterized specifically for a different safety profile Kenwood 2014, with subsequent metabolic work Alexopoulos 2020 Axelrod 2020 and a review of its position Xiong 2023.
  2. Total energy expenditure, most of which is not adjustable by anything here. Resting metabolic rate is dominated by organ and lean tissue mass, and the reduction that follows weight loss has been attributed to both tissue loss and metabolic adaptation Martin 2022. Any pharmacological increase in cellular energy expenditure is being added on top of that, and the arithmetic is less favorable than the mechanism sounds.
  3. WHETHER THE PREMISE OF THE COFACTOR HALF STILL HOLDS. Human whole-blood NAD+ levels were reported not to vary with age or with lifestyle interventions Tretowicz 2026. Chronic nicotinamide riboside supplementation is well tolerated and raises the pool Martens 2018. Both of those can be true: the pharmacology works and the deficit it corrects may not exist in the compartment measured. The full argument is at NAD+ & sirtuin signaling and it applies to a third of this page's item list.
  4. Species, because this is the most rodent-dependent page in the estate. The transcriptional and metabolic results behind the receptor agonists are animal and cell work. Where a human-adjacent result exists it usually undercuts the story rather than supporting it: SR9009's effects have been shown to be partly independent of the receptor it is named for Dierickx 2019.
  5. What the compound does to fatty acid handling rather than to expenditure. Meldonium's biochemical mechanisms and pharmacological effects have been reviewed Dambrova 2016, and its action is a shift in substrate use rather than an increase in burn. Substrate shifting and energy dissipation are different claims and this page mixes them.
  6. Whether the mitochondrial peptides do anything without exercise. MOTS-c was reported to interact synergistically with exercise intervention Yang 2021, which is a preclinical result and also a hint: the interesting claim in this family is conditional on training rather than independent of it.

The order to run these in, and what has to be true first

This is a page where the ordering is mostly a list of things to understand before spending, because the human evidence is thin and the risk at one end is real.

  1. Baseline bloods before anything on this page. A Comprehensive Metabolic Panel (CMP), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), HbA1c (Hemoglobin A1c), Fasting Insulin, Complete Blood Count (CBC) with Differential, hs-CRP (High-Sensitivity C-Reactive Protein) and Free T3 (Triiodothyronine) with TSH (Thyroid-Stimulating Hormone). Thyroid status is the physiological version of what several compounds here are attempting pharmacologically, and it is the first thing to rule out; the page for it is Thyroid & thermogenic substrate.
  2. CoQ10, PQQ, Alpha Lipoic Acid and Acetyl-L-Carnitine are the cofactor end and the lowest-risk entry. They support respiratory chain function rather than uncouple it, and their evidence is discussed at Mitochondrial ATP production.
  3. NR, NR (Nicotinamide Riboside), NMN and Nad+ are the precursor arm, and the premise question comes first. The pharmacology raises the pool Martens 2018; whether the pool falls with age in the compartment people measure is now contested Tretowicz 2026. Buying a pharmacology with an open clinical question is a defensible decision made with open eyes.
  4. Urolithin A and Calcium AKG are quality-control and metabolite arguments rather than expenditure ones. The urolithin producer-phenotype question is documented Tomas-Barberan 2014, and the mitophagy case is at Autophagy & mitochondrial quality control.
  5. Berberine and Dihydroberberine are the energy-sensing botanicals and belong to the glucose literature, which is at AMPK activation & cellular fuel sensing and Substrate partitioning & insulin control. Dihydroberberine is an absorption argument rather than a different mechanism.
  6. Meldonium is a substrate-shifting drug with a documented mechanism Dambrova 2016 and no body-composition trial. Methylene Blue is an electron cycler with complex respiratory effects Svab 2021 and a serotonergic interaction that makes it a genuine drug rather than a supplement.
  7. Bam15 and SANA are the uncoupler end and the toxicology of the class is the reason to read before buying. BAM15 was characterized as an uncoupler with a distinct profile Kenwood 2014 and studied metabolically Alexopoulos 2020 Axelrod 2020 Xiong 2023; all of that is preclinical, and the class's human history is Grundlingh 2011.
  8. SLU-PP-332, SLU-PP-915, AICAR, ATX-304, SR-9009, Cardarine (oral/inj) Gw-501516, MOTS-c, Humanin, SS-31 and 5-Amino-1MQ are the research shelf and none has a human body-composition trial. The exercise-mimetic half of that argument is set out at Exercise mimetics & mitochondrial biogenesis, and SR9009's off-target activity Dierickx 2019 is the specific reason one of them is not the clean experiment it is sold as.

What gets bought for this that cannot move it

The category that fails structurally is the uncoupler bought without a therapeutic index. Dissipating the proton gradient produces heat, and heat production without an upper bound is how 2,4-dinitrophenol kills people — its toxicity as a weight loss agent is documented Grundlingh 2011. Newer molecules are designed against exactly that problem Kenwood 2014 Xiong 2023, which is an argument for the chemistry and not yet a demonstration of human safety, because the metabolic work is preclinical Alexopoulos 2020 Axelrod 2020. A compound bought from an unregulated source in this class has no dose control, and dose control is the entire safety mechanism.

The direction failure the arithmetic produces. Resting metabolic rate falls after weight loss through both tissue loss and adaptation Martin 2022, so a pharmacological increase in cellular expenditure is working against a moving baseline rather than on a fixed one. That is why mechanism-level enthusiasm on this page consistently overshoots what a body-composition endpoint would show — and why no item here has such an endpoint published in humans.

The premise question that applies to a third of the list. If whole-blood NAD+ does not fall with age Tretowicz 2026 then the precursor arm is correcting something that may not be a deficit, even though it reliably raises the pool Martens 2018. Both statements are supported. Holding them together is the honest position and it is not the one the category is marketed on.

The reader this page is the wrong page for. If food is a source of distress rather than a quantity problem, if eating is already restricted, or if the relationship with eating is what actually needs attention, then a mitochondrial pharmacology page is the wrong instrument and the right step is a clinician who works with eating rather than a compound that changes energy expenditure. That is not a hedge; it is the honest boundary of what this page covers.

If the goal underneath is different, so is the page. If thyroid and thermogenesis are the target, Thyroid & thermogenic substrate. If it is where the calories go rather than how many are burned, Substrate partitioning & insulin control. If it is direct lipolysis, Direct lipolysis & adrenergic drive. If it is muscle preservation, Lean-mass protection while cutting. And any fever, unexplained sweating, racing heart or confusion on anything from this page is an emergency rather than a side effect.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions. Free T3 (Triiodothyronine) and TSH (Thyroid-Stimulating Hormone) will explain more low-expenditure presentations than any compound here will treat, which is why they are drawn first; and body mass will not distinguish the effect this page claims from the effect it does not, because a change in energy expenditure and a change in tissue composition read the same on a scale.

What will fool you. Feeling warm is not evidence of a useful increase in expenditure; it is the symptom that precedes the dangerous one in this class Grundlingh 2011. Body mass moves with water, glycogen and gut contents on a scale far larger than any plausible effect here, which is why body composition rather than body mass is the measurement. Rodent metabolic results Alexopoulos 2020 Axelrod 2020 Yang 2021 are not human doses. A compound bought from an unregulated source may not be what the label says, and for an uncoupler that is a dosing error with a narrow margin. And a raised NAD+ pool is target engagement rather than an outcome Martens 2018 Tretowicz 2026.

Sources read for these sections

The other 5 routes to lose fat

Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.

Appetite & satiety signaling25 optionsDirect lipolysis & adrenergic drive15 optionsSubstrate partitioning & insulin control17 optionsThyroid & thermogenic substrate9 optionsLean-mass protection while cutting14 options

You know the goal. Skool has the plan.

This pathway is one arm of The Lose fat Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.

Open The Lose fat Blueprint in Skool →

$10/mo, cancel anytime.

← Open this pathway in the interactive Vault

Frequently asked questions

What is the mitochondrial & metabolic reprogramming pathway for lose fat?

This is the pathway Cam means when he says stretch and extrapolate. Instead of eating less, you change how much energy the cell burns and how efficiently it burns it — mitochondrial biogenesis, uncoupling, NAD+ availability, PGC-1α. Almost nothing here has a human fat-loss trial. The mechanisms are well characterized and the rodent data is often striking. That gap is the opportunity and the risk in one.

What compounds and supplements work through mitochondrial & metabolic reprogramming?

29 options are mapped to this pathway in the Vault, including Garcinia Cambogia, 7-Keto, Indolepropionamide, MOTS-c. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 4 carry clinical validation and 24 are mechanistic predictions.

How do I know if mitochondrial & metabolic reprogramming is actually my problem?

There is no direct 'mitochondrial function' blood test, which is worth saying plainly. What you can check is whether the cofactors that machinery needs are present — carnitine, CoQ10, thiamine, magnesium. Deficiency here explains fatigue-with-normal-labs, and correcting it is cheaper and better evidenced than anything else in this pathway. The markers worth checking are Carnitine, Total and Free, Coenzyme Q10, Vitamin B1 (Thiamine), Magnesium, RBC.

Are the 24 theoretical options for mitochondrial & metabolic reprogramming worth considering?

Unproven is not the same as ineffective. Of the 29 options on this pathway, 4 have clinical validation and 24 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.

Where this goes next

Test itMetabolic Health & PrediabetesThe panel that says whether this is your problemGo deeperThe Fat Loss BlueprintThe free week-by-week structure behind this goal
The full protocol$10/mo

Everything above is the free case for Mitochondrial & metabolic reprogramming. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.

The Fat Loss Blueprint
Educational and research reference only — not medical advice, and not a recommendation for human use. Mechanistic predictions are exactly that: what the biology suggests should happen, which is not the same as what has been shown to happen.

↑ Back to on this page

The blueprint this pathway sits insideThe Fat Loss Blueprint →The full 16-week stack this pathway belongs to — every arm, the sequence, and the bloodwork.